Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
16. März 2023 16:04 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates
10. August 2020 16:01 ET
|
Abeona Therapeutics Inc.
Additional patients dosed in RDEB, MPS IIIA and MPS IIIB clinical programs General alignment with CHMP on plans for EU registration of ABO-102 for MPS IIIA Data from RDEB and MPS III programs...
Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual Meeting
10. Juli 2020 07:30 ET
|
Abeona Therapeutics Inc.
EB-101 treatment of large, chronic wounds is associated with durable healing and pain relief in patients with RDEBLiterature review of 65 studies confirms and expands understanding of substantial...
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Commercial Officer
09. Juli 2020 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 09, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Michael...
Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies
08. Juli 2020 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced recent updates on its clinical...
Abeona Therapeutics Announces Upcoming Data Presentations at the Society for Pediatric Dermatology 45th Annual Meeting
18. Juni 2020 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, June 18, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that two abstracts related to...
Spray-On Gene Therapy With RenovaCare SkinGun™ in New Study Underway at King’s College London
30. März 2020 08:32 ET
|
RenovaCare, Inc.
ROSELAND, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the...
Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
17. März 2020 07:30 ET
|
Abeona Therapeutics Inc.
Majority of potential study participants have been pre-screened EB-101 successfully manufactured at Abeona and transplanted at Stanford University Medical Center NEW YORK and CLEVELAND, March 17,...
Abeona Therapeutics leitet klinische Phase-3-Schlüsselstudie zur Beurteilung der Gentherapie EB-101 bei rezessiver dystropher Epidermolysis bullosa (RDEB) ein
13. Januar 2020 15:32 ET
|
Abeona Therapeutics Inc.
Die Studie ist für die Rekrutierung geöffnet und das Patientenscreening ist an der Stanford University angelaufen Das Unternehmen erwartet die Behandlung des ersten Patienten im ersten Quartal 2020 ...
Abeona Therapeutics lance un essai clinique pivot de phase 3 évaluant la thérapie génique EB-101 pour l'épidermolyse bulleuse dystrophique récessive
13. Januar 2020 15:32 ET
|
Abeona Therapeutics Inc.
Les inscriptions à l'étude sont ouvertes et la sélection des patients est en cours à l'Université de Stanford La société s'attend à ce qu'un premier patient soit traité au cours du premier trimestre...